Illumina (NASDAQ:ILMN) Given New $145.00 Price Target at UBS Group

Illumina (NASDAQ:ILMN) had its price objective boosted by UBS Group from $133.00 to $145.00 in a report released on Tuesday,Benzinga reports. They currently have a neutral rating on the life sciences company’s stock.

Other equities analysts also recently issued reports about the stock. Canaccord Genuity Group raised their price objective on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a research note on Thursday, October 17th. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective on the stock in a research note on Thursday, October 17th. Citigroup raised their target price on Illumina from $155.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Royal Bank of Canada upped their price target on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Illumina currently has an average rating of “Moderate Buy” and a consensus price target of $162.18.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $155.15 on Tuesday. Illumina has a 12 month low of $89.00 and a 12 month high of $156.66. The company has a market cap of $24.72 billion, a P/E ratio of -15.58 and a beta of 1.13. The business’s 50 day moving average is $137.27 and its two-hundred day moving average is $123.12. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 6.36%. The firm’s revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the company earned $0.33 earnings per share. On average, equities analysts expect that Illumina will post 3.62 EPS for the current year.

Institutional Investors Weigh In On Illumina

A number of large investors have recently modified their holdings of the business. First Trust Direct Indexing L.P. acquired a new stake in Illumina in the first quarter valued at about $229,000. Norden Group LLC acquired a new stake in shares of Illumina in the 1st quarter valued at approximately $584,000. Private Advisor Group LLC grew its holdings in shares of Illumina by 4.8% during the 1st quarter. Private Advisor Group LLC now owns 4,955 shares of the life sciences company’s stock valued at $679,000 after purchasing an additional 226 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Illumina by 41.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 3,070 shares of the life sciences company’s stock worth $422,000 after purchasing an additional 900 shares in the last quarter. Finally, Nordea Investment Management AB lifted its stake in Illumina by 5.8% in the 1st quarter. Nordea Investment Management AB now owns 14,382 shares of the life sciences company’s stock valued at $1,981,000 after purchasing an additional 784 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.